Biosphere Launches UV Bioreactor to Transform Industrial Fermentation
Following $8.8m seed round, Biosphere aims to slash biomanufacturing’s capital costs by more than 50% OAKLAND, Calif., Jan. 09, 2025...
Year: 2025
Ori Biotech Expands Team to Advance IRO Commercialization and Industry Partnerships
Company Making Additions to Executive Team and Advisory Board to Support Significant Commercial MomentumLONDON, Jan. 09, 2025 (GLOBE NEWSWIRE) --...
IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer
-- Enrollment Completed Ahead of Schedule -- -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE...
Amwell® divests virtual psychiatric care business to Avel eCare in all-cash transaction
Divestment of Amwell Psychiatric Care intended to focus product portfolio on key growth initiatives Company reiterates guidance for 2024 BOSTON,...
Frontier Medicines Announces FMC-220, the First Covalent p53 Y220C Activator Development Candidate, with Best-in-Class Potential
FMC-220 is a first-in-class covalent activator of p53Y220C designed to address potency and tolerability challenges of non-covalent approachesIn preclinical studies,...
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company...
Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference
The panel will discuss the value proposition for investing in women’s health. J.P. Morgan is hosting a three-panel women’s health...
Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings
Phase 1 INTERCEPT-AD data published in Journal of Prevention of Alzheimer’s Disease supports continued development of sabirnetug (ACU193) for treatment...
New England Life Care Selects Inovalon’s ScriptMed® to Scale Infusion Therapy and Specialty Pharmacy
ScriptMed Infusion will Accelerate New England Life Care's Patient-Centric Care and Scale Pharmacy OperationsBOWIE, Md., Jan. 09, 2025 (GLOBE NEWSWIRE)...
Boehringer Ingelheim Acquires Fourth License for the Development of Novel Antibody Based Cancer Treatments from Oxford BioTherapeutics
Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a...
ElevateBio to Present at the 43rd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering the creation of...
Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on...
TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Presentation scheduled for Monday, January 13, 2025, at 4:30 PM PTNEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics,...
Ribometrix Strengthens Leadership, Appoints William S. Marshall, Ph.D., as Chief Executive Officer and Katie Warner, Ph.D., as Chief Scientific Officer
Revolutionary direct RNA-targeting technology opening a new frontier of prohibiting the production of proteins associated with diseaseDURHAM, N.C., Jan. 09,...
Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors
World-renowned researcher brings expertise in obstetrics and gynecology from Yale University to advance Eterna’s lead indication in ovarian cancerCAMBRIDGE, Mass.,...
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
MELBOURNE, Australia and SAN FRANCISCO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the...
Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates
New SER-155 Phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients demonstrate that SER-155 promoted epithelial...
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219’s Transformative Potential for CNS Disorders
In the PET trial, RAP-219 achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the...
Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies
Azenosertib Fast Track Designation granted for Cyclin E1 positive patients by U.S. Food and Drug Administration (FDA) Manuscript focused on role...
Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy
Transaction Expands Climb Bio’s Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated Diseases New Program is a Highly Potent, Fc-engineered...